Previous opportunities are listed below to offer interested investigators an opportunity to view funding that may be offered again in the future. Details are subject to change.
-
Previous Funding Opportunities for Junior Faculty
Previous Funding Opportunities for Junior Faculty
AACR-Aflac Incorporated Career Development Award for Pediatric Cancer Research
The AACR-Aflac Inc. Career Development Award for Pediatric Cancer Research represents a joint effort to encourage and support junior faculty who are in the first five years of a faculty appointment (at the start of the grant term) to conduct pediatric cancer research and establish successful career paths in this field. The research proposed for funding may be basic, translational, clinical or epidemiological in nature and must have direct applicability and relevance to pediatric cancer. The grant provides $100,000 over two years ($50,000 per year) for direct research expenses, which may include salary and benefits of the grant recipient, postdoctoral or clinical research fellows, and/or research assistants, research/laboratory supplies and equipment.
Top of Page
AACR-FNAB Career Development Award for Translational Cancer Research
The AACR-FNAB Career Development Award for Translational Cancer Research is open to junior faculty who are in the first four years of a faculty appointment (at the start of the grant term). Research projects are restricted to translational cancer research focused on any individualized therapeutic area. Proposed project must have implications for individualized cancer treatment and must make use of human biopsies or samples, such as needle biopsies or circulating cancer cells. In vivo primary tumor explants meet these criteria, but xenografts from established cell lines do not. This is a two-year grant of $100,000 ($50,000 per year) for direct research expenses and salary support.
Top of Page
AACR-Genentech BioOncology Career Development Award for Cancer Research on the HER Family Pathway
The AACR-Genentech BioOncology Career Development Award for Cancer Research on the HER Family Pathway represents a joint effort to encourage and support physician-scientists who are within the first five years of a faculty appointment (at the start of the grant term) to conduct cancer research on the HER family pathway and establish successful career paths in this field. Proposed research projects are restricted to basic, translational, clinical or epidemiological projects that substantially advance the field of cancer research on the HER family pathway. The grant provides $150,000 over two years ($75,000 per year) for direct research expenses, which may include salary and benefits of the grant recipient, postdoctoral or clinical research fellows, and/or research assistants, research/laboratory supplies and equipment.
Top of Page
AACR Gertrude B. Elion Cancer Research Award
The AACR Gertrude B. Elion Cancer Research Award is open to tenure-track scientists at the level of assistant professor who are in the first five years of a faculty appointment (at the start of the grant term). Proposed research projects may focus on research in cancer etiology, diagnosis, treatment or prevention (basic, translational or clinical cancer research). The award provides a one-year grant of $75,000 for direct research expenses.
About Gertrude B. Elion
This award honors the late Dr. Gertrude B. Elion, scientist emeritus at Glaxo Wellcome Co. (now GlaxoSmithKline). Her seminal research at the company revolutionized cancer therapeutics and her prolific contributions to biomedical science earned her the Nobel Prize in Physiology or Medicine in 1988. The AACR is extremely pleased to sponsor this award in the name of Dr. Elion, a distinguished past president and honorary member of the AACR.
Top of Page
AACR Judah Folkman Career Development Award for Antiangiogenesis Research
The AACR Judah Folkman Career Development Award for Antiangiogenesis Research represents a joint effort to encourage and support junior faculty who are in the first four years of a faculty appointment (at the start of the grant term) to conduct cancer research and establish successful career paths in this field. Applicants must have a medical degree (M.D., D.O. or international equivalent), or hold a combined M.D./Ph.D., and be affiliated with an institution in the U.S. Proposed research projects are restricted to basic, translational, clinical or epidemiological projects that substantially advance the field of antiangiogenesis research in cancer.
The grant provides $100,000 over two years ($50,000 per year) for direct research expenses, which may include the salary and benefits of the grant recipient, postdoctoral or clinical research fellows and/or research assistants, research/laboratory supplies and equipment.
Top of Page
AACR-National Brain Tumor Society Career Development Award for Translational Brain Tumor Research
The AACR-National Brain Tumor Society Career Development Award for Translational Brain Tumor Research represents a joint effort to encourage and support junior faculty who are in the first five years of a faculty appointment (at the start of the grant term) to conduct brain tumor research and establish successful career paths in this field. The research proposed for funding must be translational in nature and have direct applicability and relevance to brain tumors.
The award provides $150,000 over two years ($75,000 per year) for direct research expenses; which may include the salary and benefits of the grant recipient, postdoctoral or clinical research fellows, and/or research assistants, research/laboratory supplies and equipment.
Top of Page
Fight Colorectal Cancer-AACR Career Development Award, in memory of Lisa Dubow
The Fight Colorectal Cancer-AACR Career Development Award, in memory of Lisa Dubow, is eligible to junior faculty who are in the first four years of a faculty appointment at the initiation of the grant term. Eligible research projects are restricted to translational or clinical research that focuses on novel THERAPEUTIC APPROACHES for late-stage metastatic colorectal cancer. This grant will support a project designed to lead to individualized therapeutic options for treatment or the development of promising new cancer therapeutics for patients with metastatic colorectal cancer. Emphasis will be placed on proposed projects which will translate into clinical applications within a few year period, including those with predictive biomarker studies.
The award provides $100,000 over two years ($50,000 per year) for direct research expenses, which may include salary and benefits of the grant recipient, postdoctoral or clinical research fellows, and/or research assistants and research/laboratory supplies.
Top of Page
Landon Foundation-AACR INNOVATOR Award for Cancer Prevention Research
The Landon Foundation-AACR INNOVATOR Award for Cancer Prevention Research was established to recognize the outstanding achievement of a junior faculty-level scientist working in the field of cancer prevention, and support his or her novel and innovative research that, if successful, will have strong potential for high impact in the cancer prevention field.
The goals of the grant program are to encourage an outstanding, creative young investigator to pursue novel, high-risk, high-reward cancer prevention research by providing the support that otherwise may not be available through traditional funding. Travel support is included to help foster interactions among cancer scientists working in various disciplines and to disseminate scientific knowledge about cancer prevention research throughout the field.
Proposed projects may differ from current accepted practice and break new ground or extend previous findings in new directions and therefore, may not be supported by substantial preliminary data. Accordingly, such projects will be evaluated based on the conceptual framework, the level of innovation, and the potential for high reward.
The grant provides $100,000 over two years ($50,000 per year) for direct research expenses; which may include the salary and benefits of the grant recipient, postdoctoral or clinical research fellows, and/or research assistants, research/laboratory supplies and equipment; and for attendance at an AACR Annual Meeting, AACR Frontiers in Cancer Prevention Research Conference, or other AACR meeting for the purpose of participating in scholarly exchange about the funded research.
About the Kirk A. & Dorothy P. Landon Foundation
The Kirk A. and Dorothy P. Landon Foundation was created through a bequest from Mrs. Dorothy P. Landon whose intent, along with that of her late husband, Kirk A. Landon, was to dedicate a major portion of their estate to medical research, especially research related to cancer. Mr. R. Kirk Landon, son of Kirk A. Landon, serves as the president of the foundation. The foundation seeks to accomplish its cancer research mission through a variety of programs and initiatives, including the Landon-AACR INNOVATOR Awards.
Top of Page
Pancreatic Cancer Action Network-AACR Career Development Awards
The Pancreatic Cancer Action Network-AACR Career Development Awards represent a joint effort to encourage and support junior faculty who are in the first five years of a faculty appointment (at the start of the grant term) to conduct pancreatic cancer research and establish successful career paths in this field. The research proposed for funding may be basic, translational, clinical or epidemiological in nature and must have direct applicability and relevance to pancreatic cancer.
The grant provides $200,000 over two years ($100,000 per year) for direct research expenses, which may include salary and benefits of the grant recipient, postdoctoral or clinical research fellows, and/or research assistants, research/laboratory supplies and equipment.
Research projects must have direct applicability and relevance to pancreatic cancer. They may be in any discipline of basic, clinical, translational or epidemiological research, and fall within at least one of the categories of the Common Scientific Outline (Biology; Etiology; Prevention; Early Detection, Diagnosis, and Prognosis; Treatment; Cancer Control, Survivorship, and Outcomes Research; or Scientific Model Systems [https://www.icrpartnership.org/CSO.cfm]).
Generously Supported By
Pancreatic Cancer Action Network
Top of Page
Pancreatic Cancer Action Network-AACR Research Acceleration Network Grant
| Letter of Intent deadline: |
October 8, 2012 at noon Eastern Time |
| Applicants notified of LOI status: |
Early December 2012 |
Application deadline: (for those invited to apply):
|
January 15, 2013 at noon, ET |
| Decision date: |
March 2013 |
| Annual Grants Reception and Dinner at AACR Annual Meeting 2013: |
April 9, 2013 |
| Start of grant term: |
July 1, 2013 |
| Pancreatic Cancer Action Network Gala Weekend: |
October/November 2013 and October/November 2014 |
Program Summary
The goal of the Pancreatic Cancer Action Network-AACR Research Acceleration Network (RAN) Grant is to provide funding and strategic assistance to a research project with the potential to double the survival rate from pancreatic cancer by the year 2020. The project must be implemented by a multi-institutional team and include a clinical component with an endpoint relevant to improving the detection or treatment of pancreatic cancer. The RAN Grant will provide $1,000,000 in funding over a one- to three-year timeframe. In addition to the grant, the Pancreatic Cancer Action Network will provide strategic project management support to help optimize project implementation and progress during the grant term.
Research Project Criteria
The basis for the RAN Grant is the recognition that there is basic, translational, clinical and epidemiological research already underway within the pancreatic cancer community that provides a strong foundation and significant resources that could be brought to bear on the 2020 goal of doubling the survival rate for pancreatic cancer. The RAN Grant is designed to streamline and accelerate progress and effect the desired change in clinical outcome for this disease by linking synergistic capabilities, providing an efficient management structure, and providing funds that can be rapidly and strategically deployed. The project that is selected for a RAN Grant will leverage existing knowledge and experience and be milestone- and timeline-driven. The RAN Grant project must have a clinical component implemented at least by the third year of the funding period. It is recognized that the RAN Grant project is likely to represent a critical step in a longer-term project with a projected completion date of 2020, requiring clinical research beyond the budget and time scope of the RAN Grant. In this case, a plan that outlines the subsequent studies and feasibility of their completion should be provided to allow an assessment of the potential to reach the goal of doubling survival by 2020. Clinical impact, scientific validity and feasibility are overriding evaluation criteria in selecting the project to be funded by the RAN Grant.
The following scenarios are considered areas where there are sufficient developments within the pancreatic cancer field that could benefit from strategic acceleration. Note these are examples, and applications for the RAN Grant are not restricted to projects that conform to these scenarios:
- An immunotherapy approach that clinically tests combinations of a previously-tested vaccine with one or several immune modifying factors;
- Preclinical testing of rational combinations of chemotherapeutic agents currently in early phase clinical development and initial combination clinical trials. A plan is included for subsequent clinical testing of resulting promising combinations if this exceeds the timeframe or budget of the RAN Grant;
- Neoadjuvant clinical study with tumor tissue for predictive and/or pharmacodynamic marker development;
- Adaptive clinical trial incorporating multiple targeted agents and predictive biomarkers;
- Clinical bioavailability studies for a promising imaging agent and the initiation of studies in a high-risk cohort;
- Large retrospective study with samples from multiple sites for an early detection or predictive serum biomarker panel with a feasible strategic plan for a prospective study (The prospective study may be outside of the RAN Grant budget or timeframe but feasibly completed by 2020.).
Proposed RAN Grants must fall within at least one of the categories of the Common Scientific Outline (Biology; Etiology; Prevention; Early Detection, Diagnosis and Prognosis; Treatment; Cancer Control, Survivorship, and Outcomes Research; or Scientific Model Systems [https://www.icrpartnership.org/CSO.cfm]).
Program Guidelines and Application Instructions
Generously Supported By
Pancreatic Cancer Action Network
Top of Page
*Adobe Acrobat Reader required
Inquiries
Hanna Hopfinger, Program Associate
Telephone: (215) 446-7191
Fax: (215) 440-9372
Email:
grants@aacr.org